Given the therapeutic roles of IL-17A in psoriasis30–33 and the pathological features of macrophage infiltration around the epidermal-dermal interface in psoriasis patients34,35, we conducted in vivo experiments to evaluate the efficacy of our IL-17A-clearing LYTACAs for treating psoriasis. This evidence concerns the gene IL17A and psoriasis.